Discounted Cash Flow (DCF) Analysis Unlevered

180 Life Sciences Corp. (ATNF)

$0.685

-0.02 (-2.37%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.685 | undervalue

Operating Data

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
EBITDA --------
EBITDA (%)
EBIT --------
EBIT (%)
Depreciation --------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash --------
Total Cash (%)
Account Receivables --------
Account Receivables (%)
Inventories --------
Inventories (%)
Accounts Payable --------
Accounts Payable (%)
Capital Expenditure --------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.685
Beta 0.414
Diluted Shares Outstanding 18.15
Cost of Debt
Tax Rate 0.11
After-tax Cost of Debt 4.99%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.659
Total Debt -
Total Equity 12.44
Total Capital 12.44
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
EBITDA --------
EBIT --------
Tax Rate 0.04%0.19%0.11%0.11%0.11%0.11%0.11%0.11%
EBIAT --------
Depreciation --------
Accounts Receivable --------
Inventories --------
Accounts Payable --------
Capital Expenditure -0.14-------
UFCF --------
WACC
PV UFCF --------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5.66
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -8.22
Equity Value -
Shares Outstanding 18.15
Equity Value Per Share -